<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="882">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603677</url>
  </required_header>
  <id_info>
    <org_study_id>20-10063H</org_study_id>
    <nct_id>NCT04603677</nct_id>
  </id_info>
  <brief_title>Northern Colorado COVID-19 Biobank</brief_title>
  <acronym>NoCo-CoBio</acronym>
  <official_title>Northern Colorado Coronavirus Biobank: A Biorepository for Acute and Convalescent Patient Samples From Coloradoans Infected With SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colorado State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Colorado Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Colorado State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NoCo-CoBio Project is a biobanking effort to store and preserve saliva, nasopharyngeal,&#xD;
      stool and blood specimens from SARS-CoV-2 PCR (polymerase chain reaction) positive&#xD;
      individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have created a biorepository of stool, saliva, nasopharyngeal swab&#xD;
      specimens, peripheral blood mononuclear cells, serum, and plasma from SARS-CoV-2 infected&#xD;
      individuals for research purposes. The multifaceted biorepository will be used to establish&#xD;
      markers predicting various presentations of COVID-19 (coronavirus disease 2019).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 8, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of parameters for markers of SARS-CoV-2 infection and predictors for severe disease</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of parameters for markers of SARS-CoV-2 infection and predictors for severe disease</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Acute phase of SARS-CoV-2 infection</arm_group_label>
    <description>Participants with an acute SARS-CoV-2 infection. Intervention will not be implemented in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Convalescent phase of SARS-CoV-2 infection</arm_group_label>
    <description>Participants with a previous diagnosis of SARS-CoV-2 infection, now in the convalescent phase of disease. Intervention will not be implemented in this study.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, stool, saliva, nasopharyngeal swab specimens&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators aim to enroll individuals who have had a positive SARS-CoV-2 PCR, with a&#xD;
        goal of enrolling 100 hospitalized patients with acute SARS-CoV-2 infection, as well as 100&#xD;
        convalescent participants.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Those who have had a positive SARS-CoV-2 PCR test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  under 18 years of age&#xD;
&#xD;
          -  pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bridget Baxter</last_name>
    <role>Study Director</role>
    <affiliation>Colorado State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Colorado State University</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Hospital, UCHealth</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greeley Hospital, UCHealth</name>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <zip>80634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of the Rockies, UCHealth</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 25, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Colorado State University</investigator_affiliation>
    <investigator_full_name>Elizabeth P Ryan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>biobank</keyword>
  <keyword>biorepository</keyword>
  <keyword>SARS-CoV-2 infection</keyword>
  <keyword>COVID-19</keyword>
  <keyword>coronavirus</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

